Quarterly report · Q2
9265.TEDINET S100PWJZ
Period2022-06-01 → 2022-11-30
Filed2023-01-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥27.7bn | 2022-06-01 → 2022-11-30 | Cons. | Net sales |
| Revenue | ¥55.1bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.3bn | 2021-06-01 → 2021-11-30 | Cons. | Net sales |
| Operating income | ¥598m | 2022-06-01 → 2022-11-30 | Cons. | Operating income |
| Operating income | ¥663m | 2021-06-01 → 2021-11-30 | Cons. | Operating income |
| Ordinary income | ¥624m | 2022-06-01 → 2022-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥701m | 2021-06-01 → 2021-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥20m | 2022-06-01 → 2022-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥713m | 2021-06-01 → 2021-11-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥201m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥696m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥471m | 2021-06-01 → 2021-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥204m | 2022-06-01 → 2022-11-30 | Cons. | Profit loss |
| Net income | ¥471m | 2021-06-01 → 2021-11-30 | Cons. | Profit loss |
| Total assets | ¥22.9bn | at 2022-11-30 | Cons. | Assets |
| Total assets | ¥24.1bn | at 2022-05-31 | Cons. | Assets |
| Total assets | ¥25.1bn | at 2021-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥15.3bn | at 2022-11-30 | Cons. | Liabilities |
| Total liabilities | ¥16.1bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.6bn | at 2022-11-30 | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2021-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.8bn | at 2022-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2022-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2021-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2021-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.9bn | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥581m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥751m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥88m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥318m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥209m | 2022-06-01 → 2022-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥229m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥229m | 2021-06-01 → 2021-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-78.98 | 2022-06-01 → 2022-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-143.68 | 2022-09-01 → 2022-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥272.67 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥184.81 | 2021-06-01 → 2021-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥128.29 | 2021-09-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.2% | at 2022-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.3% | at 2021-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2022-11-30 | −¥11m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2022-11-30 | −¥11m |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2022-11-30 | −¥447m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥140m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥3m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥27.5bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥27.5bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥11m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥1.0bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2022-06-01 → 2022-11-30 | ¥33m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2022-06-01 → 2022-11-30 | ¥33m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2022-06-01 → 2022-11-30 | ¥0 |
| —segment total | revenue | 2022-06-01 → 2022-11-30 | ¥27.7bn |
| —segment total | revenue external | 2022-06-01 → 2022-11-30 | ¥27.7bn |
| —segment total | revenue intersegment | 2022-06-01 → 2022-11-30 | ¥11m |
| —segment total | segment profit | 2022-06-01 → 2022-11-30 | ¥1.0bn |
| Reconciling Itemsreconciling | revenue | 2021-06-01 → 2021-11-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2021-06-01 → 2021-11-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2021-11-30 | −¥415m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥136m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥136m |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2021-06-01 → 2021-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥3m |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥27.2bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥27.2bn |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | revenue intersegment | 2021-06-01 → 2021-11-30 | ¥0 |
| jpcrp040300-q2r_E33393-000Medical Equipment Salesreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥1.1bn |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue | 2021-06-01 → 2021-11-30 | ¥34m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | revenue external | 2021-06-01 → 2021-11-30 | ¥34m |
| jpcrp040300-q2r_E33393-000Medical Mallreportable segment | segment profit | 2021-06-01 → 2021-11-30 | ¥0 |
| —segment total | revenue | 2021-06-01 → 2021-11-30 | ¥27.3bn |
| —segment total | revenue external | 2021-06-01 → 2021-11-30 | ¥27.3bn |
| —segment total | revenue intersegment | 2021-06-01 → 2021-11-30 | ¥0 |
| —segment total | segment profit | 2021-06-01 → 2021-11-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 487
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 348400 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1365 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 272952 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1069 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 140100 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0549 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 130000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0509 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 129832 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0509 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 93900 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0368 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 76300 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0299 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 70000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0274 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 62000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0243 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 47800 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0187 | |
| Number of shares held | CurrentQuarterInstant | 1371284 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5372 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 100 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 2549000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 25490 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 3900 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 2553000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 25490 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0000 | |
| Cash and deposits | Prior1YearInstant | 3975000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 1812000000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 11906000000 | JPY |
| Notes and accounts receivable trade and contract assets | CurrentQuarterInstant | 12366000000 | JPY |
| Merchandise | Prior1YearInstant | 2683000000 | JPY |
| Merchandise | CurrentQuarterInstant | 3230000000 | JPY |
| Other ca | Prior1YearInstant | 245000000 | JPY |
| Other ca | CurrentQuarterInstant | 276000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -17000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -18000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |